Vedanta Biosciences, Inc.

Quick facts

Phase 3 pipeline

• VE303 · Gastroenterology
  VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease.

Phase 1 pipeline

• VE800

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vedanta Biosciences, Inc. portfolio CI brief
• Vedanta Biosciences, Inc. pipeline updates RSS